|
1) Brugarolas J. Renal-cell carcinoma‐Molecular pathways and therapies. N Engl J Med. 2007; 356: 185-7
|
|
|
|
2) Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-34
|
|
|
|
|
|
3) Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-11
|
|
|
|
|
|
4) Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007: 356(2): 125-34
|
|
|
|
|
|
5) Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-37
|
|
|
|
|
|
6) Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-24
|
|
|
|
|
|
7) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24
|
|
|
|
|
|
8) Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81
|
|
|
|
|
|
9) Motzer RJ, et al. for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56
|
|
|
|
|
|
10) Rini BI, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007; 99: 81-3
|
|
|
|
|
|
11) Chu TF, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370: 2011-9
|
|
|
|
|
|
12) Khakoo AY, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008; 112: 2500-8
|
|
|
|
|